[HTML][HTML] Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
CE Mire, RW Cross, JB Geisbert, V Borisevich… - Nature medicine, 2017 - nature.com
CE Mire, RW Cross, JB Geisbert, V Borisevich, KN Agans, DJ Deer, ML Heinrich…
Nature medicine, 2017•nature.comThere are no approved treatments for Lassa fever, which is endemic to the same regions of
West Africa that were recently devastated by Ebola. Here we show that a combination of
human monoclonal antibodies that cross-react with the glycoproteins of all four clades of
Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at
advanced stages of disease, including up to 8 d after challenge.
West Africa that were recently devastated by Ebola. Here we show that a combination of
human monoclonal antibodies that cross-react with the glycoproteins of all four clades of
Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at
advanced stages of disease, including up to 8 d after challenge.
Abstract
There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.
nature.com